2002
DOI: 10.1212/wnl.59.3.466
|View full text |Cite
|
Sign up to set email alerts
|

Amiodarone and acetazolamide for the treatment of genetically confirmed severe Andersen syndrome

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
17
0
2

Year Published

2007
2007
2024
2024

Publication Types

Select...
7
1

Relationship

1
7

Authors

Journals

citations
Cited by 59 publications
(19 citation statements)
references
References 5 publications
0
17
0
2
Order By: Relevance
“…Aborted sudden deaths have also been reported in the past (Junker, et al, 2002). It is much too early to conclude that arrhythmias in ATS are, for the most part, benign.…”
Section: Discussionmentioning
confidence: 99%
“…Aborted sudden deaths have also been reported in the past (Junker, et al, 2002). It is much too early to conclude that arrhythmias in ATS are, for the most part, benign.…”
Section: Discussionmentioning
confidence: 99%
“…However all of these options rely on case report or small series reporting of efficacy 12 . The majority of published data relates to the use of carbonic anhydrase inhibitors, acetazolamide and dichlorphenamide that have been used as prophylactic agents in all the periodic paralyses [13][14][15] although their exact mode of action is incompletely understood 16 . In 2002 Merck ceased production of dichlorphenamide and it has been unavailable worldwide since 2011.…”
Section: What Are the Unmet Needs Of Currently Available Therapies?mentioning
confidence: 99%
“…Treatment of ATS patients requires closely co-ordinated expertise between a neuromuscular specialist and a cardiologist. However, it has been observed that drugs may have beneficial effect on one tissue while detrimental on other, but amiodarone and acetazolamide are effective in many cases (Junker et al 2002).…”
Section: Andersen Tawil Syndrome (Ats)mentioning
confidence: 99%